New Study Finds Pepto Bismol May Not Prevent Traveler's Diarrhea

A recent study conducted by researchers from the U.S. Centers for Disease Control and Prevention (CDC) suggests that Pepto Bismol, known for its stomach-soothing properties, might not be effective in preventing diarrhea during international travel. The study, which examined 270 adults planning trips to regions in Southeast Asia, South Central Asia, North Africa, and sub-Saharan Africa, compared the effects of bismuth subsalicylate—the active ingredient in Pepto Bismol—against a placebo. Participants were instructed to take four tablets twice daily while traveling, with data collected through questionnaires before, during, and after their trips.

The findings, published in the Journal of Travel Medicine, indicated no significant difference in the incidence of diarrhea or loose stools between those who took the medication and those who did not. Despite Pepto Bismol's long-standing approval by the FDA since 1939 for treating gastrointestinal issues such as diarrhea, indigestion, and nausea, its preventive use during travel appears to lack strong scientific support.

This research marks the first considerable evaluation of its kind since the 1980s and casts doubt on the common practice of recommending Pepto Bismol specifically for travel-related diarrhea prevention. The study's results suggest that healthcare providers should reconsider advising travelers to rely on this medication for prevention purposes. However, the researchers noted that more extensive studies are necessary to definitively determine the medication's effectiveness, as a larger sample size might reveal small benefits not detected in this trial.

The medication used in the study was supplied by Procter & Gamble, but the company had no involvement in the research process. The authors emphasize the importance of re-evaluating travel health guidelines and highlight the need for further investigation into preventive strategies.